Who Paid My Doc
Triferic
Drug End Stage Renal Disease
NDC 57278-315-02
General payments
$486,953
Research payments
$578,904
Through program year 2021, $486,953 in general payments and $578,904 in research payments were reported against Triferic (End Stage Renal Disease).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | General | $35,278 | 39 |
| 2021 | Research | $127,484 | 31 |
| 2020 | General | $235,406 | 169 |
| 2020 | Research | $402,439 | 32 |
| 2019 | General | $216,268 | 135 |
| 2019 | Research | $48,981 | 4 |
Breakdown
The top 5 of 29 recipients; each share is of general payments naming this product in 2021.
The top 5 of 7 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.
The top 5 of 19 states; each share is of general payments naming this product in 2021 where a state was reported.
Records
343 general · 67 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.